al., 2012). Additionally, data from large pen feedlot studies have indicated that Zn may elicit a similar response in RAC-fed finishing cattle (Larson and Branine, 2015) , although other research has found no additional benefit to supplementing additional Zn from Zn-propionate to finishing cattle receiving RAC (Bohrer et al., 2014; Edenburn et al., 2015; Overbeck et al., 2008) .
Zinc can also support anti-inflammatory activity and may modulate the immune response (Overbeck et al., 2008; Prasad, 2008) . This may be important as cattle are suspected to undergo a non-specific immune response during the finishing period characterized by increased peak acute phase protein concentrations (Ametaj et al., 2009; Berry et al., 2004) . The objective of this study was to determine if increasing supplemental Zn affects growth and carcass performance and markers of inflammation in finishing cattle fed RAC. The hypothesis was that increasing supplemental Zn to RAC-fed cattle would improve performance and decrease markers of inflammation.
MATERIALS AND METHODS
All procedures and protocols were approved by the Iowa State University Institutional Animal Care and Use Committee (Log number: 7-12-7411-B).
Forty-two Angus crossbred steers (380 ± 5.3 kg) were stratified by BW into 7 pens of 6 steers each (1 steer was removed due to illness unrelated to treatment) and assigned to 1 of 4 treatments for 86 d (pre-RAC period): a dry-rolled corn-based diet supplemented with 60 mg Zn/kg from ZnSO 4 (CON; analyzed 88 mg Zn/kg DM; n = 6 steers; Table 1) or CON diet supplemented with 30 (Zn30; n = 12 steers), 60 (Zn60; n = 12 steers), or 90 (Zn90; n = 11 steers) mg Zn/kg from a Zn amino-acid complex (ZnAA; Availa-Zn; Zinpro Corporation, Eden Prarie, MN). Before the start of the study steers were vaccinated against infectious bovine rhinotracheitis virus, type I and II bovine viral diarrhea, parainfluenza-3 virus, bovine respiratory syncytial virus and Mannheimia haemolytica toxoid (Pyramid 5 + Presponse; Fort Dodge Animal Health, Fort Dodge, IA), clostridial bacterin-toxoid, (Vision 7; Merck Animal Health, Summitt, NJ), and Moraxella bovis (Pinkeye Shield XT4; Novartis Animal Health Canada Inc., Hamilton, ON, Canada) and dewormed with eprinomectin (Eprinex; Merial Ltd., Iselin, NJ). Steers were implanted with Component TE-IS with Tylan (VetLife; Ivy Animal Health, Inc., Overland Park, KS) on d 28.
On d 88 one of the 2 pens of steers on treatments that included supplemental ZnAA was randomly selected to be supplemented with RAC (Optaflexx; Elanco Animal Health, Greenfield, IN) at 300 mg × steer -1 •d -1 for the final 28 d of the experiment, creating 7 final treatments (RAC period): CON: no supplemental ZnAA, no RAC (n = 5 steers); Zn30: Zn30, no RAC (n = 5 steers); Zn30R: Zn30 + RAC (n = 6 steers); Zn60) Zn60, no RAC (n = 6 steers); Zn60R: Zn60 + RAC (n = 6 steers); Zn90: Zn90, no RAC (n = 5 steers); and Zn90R: Zn90 + RAC (n = 6 steers). Two steers were removed from the experiment due to illness unrelated to treatment, and these removals are reflected in individual treatment numbers.
Steers were fitted with unique electronic identification tags and daily individual animal intake was measured using the Feed Intake Management System at Iowa State University's Beef Nutrition Farm in Ames, Iowa (Dahlke et al., 2008) . Steers were fed once daily at 0800 h, had ad libitum access to water, and were fed for approximately 3% feed refusal as previously described (Genther and Hansen, 2014) . Body weights were collected before feeding on d 0, 1, 28, 56, 86, 115, and 116 . Liver biopsies and jugular blood samples were taken on d -5, 78, and 111 (5 to 8 d before the end of each period) for determination of trace mineral status and analysis of various immune and metabolism markers. At the end of the experiment (d 116) steers were shipped to a commercial abattoir (Tyson Fresh Meats, Denison, IA) for harvest followed by a 24 h Zn, mg/kg DM 88
1 For RAC treatments during the RAC period (d 88 to d 116) corn dried distillers' grains were displaced to achieve 300 mg RAC×steer-1d-1.
2 Treatment premix used corn dried distillers' grains as the carrier and provided: CON = 0 mg Zn/kg diet DM from a Zn amino acid complex (ZnAA); Zn30 = 30 mg Zn/kg diet DM from ZnAA; Zn60 = 60 mg Zn/kg diet DM from ZnAA; Zn90 = 90 mg Zn/kg diet DM from ZnAA.
3 Vitamin A premix contained 4,400,000 IU vitamin A/kg.
4 Provided per kg of diet: 60 mg Zn; 48 mg Mn; 0.75 mg I; 0.24 mg Se; 17.6 mg Cu; and 0.38 mg Co (all inorganic sources); concentrations from Vasconcelos and Galyean (2007) . 5 Provided at 27 g/909.1 kg of diet (donated by Elanco Animal Health, Greenfield, IN).
6 Chemical analysis was completed by Dairyland Laboratories (Arcadia, WI).
chill. Personnel from Tri County Steer Carcass Futurity (Lewis, IA), blinded to treatments, collected carcass data, including: HCW, REA, ΒF, KPH, marbling score (MS), quality grade (QG), and yield grade (yG). A 4% pencil shrink was applied to all live BW measures before the calculation of ADG and G:F.
Feed and Tissue Sampling and Analysis. Total mixed rations (TMR) were sampled weekly, and samples were dried in a forced-air oven at 70°C for 48 h for DM determination. Steer DMI was calculated using as-fed intakes corrected for DM of weekly diet samples. Feed efficiency (G:F) was calculated from the total gain and total DMI monthly as determined by weighing intervals. Diet samples were ground through a 2-mm screen in a Wiley Mill (Thomas Scientific, Swedesboro, NJ), and samples were composited by treatment by month for trace mineral analysis. Composited feeds were acid digested using trace mineral grade nitric acid as previously described (Genther and Hansen, 2014) before analysis for Cu, Fe, and Zn concentrations using inductively coupled plasma optical emission spectroscopy (PerkinElmer, Waltham, MA). Liver biopsies were taken using the method of Engle and Spears (2000) , and liver samples were dried and acid digested, followed by analysis for Cu, Fe, and Zn as described previously (Pogge and Hansen, 2013) . A bovine liver reference sample from National Institutes of Standards and Technology (Gaithersburg, MD) was included in all analyses to verify instrument accuracy. Blood samples (collected in tubes containing either no additive for serum, K 2 EDTA for TM analysis, or sodium heparin for other analyses) were spun in a centrifuge at 1,200 × g for 10 min at 4°C and serum or plasma was removed and stored at -80°C until analysis. Plasma samples were analyzed for Cu, Fe, and Zn using methods previously described (Pogge and Hansen, 2013) . A human serum reference sample from UTAK Laboratories Inc. (Valencia, CA) was included in all analyses to verify instrument accuracy. Whole blood samples were brought to the Clinical Pathology Laboratory at Iowa State University (Ames, IA) for a complete blood count and automated differentiation of leukocytes immediately after collection into tubes containing K 2 EDTA. Serum was sent to the Kansas State University Diagnostic Laboratory (Manhattan, KS) for haptoglobin analysis using the method described by Smith et al., (1998) . Serum interleukin-8 (IL-8) concentration was analyzed using a commercial ELISA kit shown to cross-react with bovine samples (Quanitkine ELISA, Human CXCL8/IL-8; R & D Systems, Minneapolis, MN; Catalog number D8000C). Serum interleukin-6 concentration was measured using a bovine-specific ELISA assay (SearchLight; Aushon Biosystems Inc., Billerica, MA). Plasma samples for cAMP analysis were purified by the addition of ice-cold ethanol, followed by centrifugation at 1500 × g. The supernatant was dried under a stream of N gas and then re-suspended in a buffer provided by the manufacturer listed below. Samples were then acetylated to increase assay sensitivity, by the addition of potassium hydroxide and acetic anhydride, and cAMP concentration was analyzed using a commercial ELISA kit (Cayman Chemical, Ann Arbor, MI; Catalog number 581001).
Single-stranded DNA breaks were evaluated through alkali single-cell gel electrophoresis (Singh et al., 1988 ) using a commercial kit (Trevigen, Inc., Gaithersburg, MD; Catalog number 4250-050-K). Whole blood samples were stored in a blood storage buffer containing Hanks Balanced Buffer Solution, 20 mM EDTA, and 10% dimethylsulfoxide. Blood samples were prepared by centrifugation at 10,000 × g and were fixed in 0.5% low-melting point agarose to microscope slides (Trevigen, Inc., Gaithersburg, MD; Catalog number 4250-050-03). Cells were lysed by submersion in a lysis solution for 1 h, then submerged in an alkali unwinding solution, followed by electrophoresis at 4°C. Samples were stained using SYBR Gold, and 50 comets per sample were scored using CometScore software (TriTek Corp., Sumerduck, VA; http://www.autocomet. com/products_cometscore.php).
Statistical Analyses. Data were analyzed by ANOVA as a completely randomized design using the MIXED procedure of SAS 9.2 (SAS Inst. Inc., Cary, NC). Steer was considered the experimental unit for all data. One steer was removed from the experiment due to illness unrelated to treatment during the pre-RAC period (Zn90), and data were not included in analysis. Two additional steers during the RAC period (CON and Zn30) were removed from the experiment due to illness unrelated to treatment, and the data from these steers were not included in RAC period analysis. The statistical model for both the pre-RAC and RAC periods included the fixed effect of dietary treatment and the random effect of steer. Day was used as a repeated effect in the case of BW, DMI, ADG, and G:F, and the subject for the repeated statement was steer nested within dietary treatment. Initial measurements for blood/tissue and performance measurements (d -5 or d 0 values for the pre-RAC period, and d 78 or d 86 values for the RAC period, respectively) were used as covariates in analysis of the data for each period. Initial ΒW (d 0) was used as a covariate for HCW. Three a priori individual degree of freedom contrasts were developed for the pre-RAC period, CON vs. Zn, which compared the CON treatment to Zn30, Zn60, and Zn90, and the linear and quadratic effects of supplemental ZnAA (CON, Zn30, Zn60, and Zn90). Six a priori individual degree of freedom contrasts were developed to evaluate the ZnAA response during the RAC period. Within the non-RAC supplemented treatments, CON vs. Zn, which com-pared the CON treatment to Zn30, Zn60, and Zn90, and the linear and quadratic effects of supplemental ZnAA (CON, Zn30, Zn60, and Zn90). Within the RAC supplemented treatments, the linear and quadratic effects of supplemental ZnAA were tested (Zn30R, Zn60R, and Zn90R). And the effect of RAC within treatments receiving supplemental ZnAA was tested as no RAC vs. RAC (Zn30, Zn60, and Zn90 vs. Zn30R, Zn60R, and Zn90R). Autoregressive 1 (AR[1]) covariance structure was utilized for all models based on lowest Akaike information criterion. Data were checked for normalcy and homogeneity of variance. Outliers were determined using Cook's D statistic and removed if Cook's D > 0.5 (one outlier was identified and removed in each of RAC period liver Cu, plasma cAMP, serum IL-8, and comet assay measurements). Data reported are least squares means ± SEM. Significance was declared at P ≤ 0.05 and tendencies were declared from P = 0.06 to 0.10.
RESuLTS
Pre-RAC Period Growth Performance. After 86 d of dietary treatment there was a tendency for a quadratic effect of Zn on BW over the course of the pre-RAC period (P = 0.10; Table 2 ), where BW decreased from CON to Zn30, increased in Zn60 steers, and decreased in Zn90 steers. There was a treatment × time interaction within BW (P = 0.05; data not shown), where there was a slight crossover between Zn90 and Zn30 steers where Zn90 steers weighed numerically more at 28 d, but numerically less at the end of the 86 d period. There were no other treatment × time interactions for DMI, ADG, or G:F (P ≥ 0.20). Dry matter intake linearly decreased as Zn concentration increased (P = 0.03), driven by the lesser DMI of both the Zn60 and Zn90 steers. Average daily gain and G:F followed the same trends as BW, with a tendency for a quadratic effect of Zn on ADG (P = 0.10), and G:F (P = 0.09) where CON and Zn30 remained similar, per- 1 Treaments: a dry-rolled corn-based diet supplemented with 60 mg Zn/kg from ZnSO 4 and no supplemental ZnAA (CON; analyzed 88 mg Zn/kg DM; n = 6) or CON diet supplemented with 30 (Zn30; n = 12), 60 (Zn60; n = 12) or 90 (Zn90; n = 11)) mg Zn/kg DM from ZnAA.
2 Contrasts: CvsZ = CON vs. Zn30, Zn60, and Zn90; LZn = the linear effect of ZnAA; QZn = the quadratic effect of ZnAA.
3 A 4% pencil shrink was applied to all live BW measures, which were also used in the calculation of ADG and G:F.
4 Day 0 BW was used as a covariate in analysis. 5 Ending weight of the pre-RAC period. formance increased to the greatest in Zn60 followed by a slight decrease in performance for Zn90 steers. Pre-RAC Period Plasma Analytes and Tissue Trace Mineral Concentrations. There was no effect of dietary Zn concentration on liver concentration of Cu or Zn, or plasma concentration of Cu and Fe during the pre-RAC period (P ≥ 0.15; Table 3 ). However, CON steers had lesser plasma Zn concentrations (P = 0.04) compared with ZnAA supplemented steers and plasma Zn concentration increased linearly with increasing dietary Zn (P = 0.04). There was a quadratic effect of dietary Zn on serum IL-8 concentration (P = 0.05), where serum IL-8 concentrations decreased from CON to Zn60, but increased in Zn90 (Table 4) . Plasma haptoglobin concentration was unaffected by treatment (P ≥ 0.60). Plasma cAMP tended to increase linearly with increasing dietary Zn concentration (P = 0.10). Total leukocyte count was greater in ZnAA supplemented steers than CON steers (P = 0.03) and tended to linearly increase with increasing dietary Zn (P = 0.06). Neutrophils tended to be lesser in CON steers (P = 0.07), and lymphocytes (P = 0.04) and basophils (P = 0.007) were lesser in CON steers compared with Zn supplemented steers. Additionally, there was a tendency (P = 0.06) for a quadratic effect of diet on eosinophils where numbers decreased as ZnAA increased from CON to Zn30 to Zn60, but Zn90 steers had the greatest numbers. Serum IL-6 was below detection limits for all treatments. Dietary Zn concentration did not impact DNA damage as measured by tail length, tail moment, and percent DNA in the tail (P ≥ 0.37).
RAC Period Growth Performance. Steers supplemented with RAC had greater final BW, ADG, and G:F during the RAC feeding period than non-RAC supplemented steers (P ≤ 0.01; Table 5 ). Additionally, there was a linear effect of Zn within RAC supplemented steers, where final ΒW, ADG, and G:F was increased linearly as dietary Zn concentration increased (P ≤ 0.03).
Carcass Characteristics. Hot carcass weight was not impacted by RAC or Zn supplementation (P ≥ 0.14; Table 6 ). There were no differences in dressing percentage, REA, or MS (P ≥ 0.11). Within steers not supplemented with RAC, the CON steers had the greatest ΒF and YG (P = 0.04), and BF tended to decrease linearly with increasing dietary Zn (P = 0.03). Kidney, pelvic, and heart fat percentage tended to decrease linearly with Zn supplementation in combination with RAC (P = 0.07) driven mainly by the decrease from Zn30R to Zn60R.
RAC Period Plasma Analytes and Tissue Trace Mineral Concentrations. Liver Cu and Zn concentrations were linearly decreased as dietary Zn increased within RAC-supplemented treatments (P ≤ 0.05; Table 7 ). Plasma Cu concentration was increased (P = 0.001; Table 7 ) and plasma Fe concentration was decreased by the addition of RAC (P = 0.04). Plasma 1 Treaments: a dry-rolled corn-based diet supplemented with 60 mg Zn/kg from ZnSO 4 and no supplemental ZnAA (CON; analyzed 88 mg Zn/kg DM; n = 6) or CON diet supplemented with 30 (Zn30; n = 12), 60 (Zn60; n = 12), or 90 (Zn90; n = 11)) mg Zn/kg DM from ZnAA.
3 Day -5 values were used as covariates in analysis.
4 cAMP = cyclic adenosine monophosphate.
5 Units = cells ×10 3 /µl.
Zn concentration tended to be greatest in the CON steers (P = 0.06) compared with non-RAC, ZnAAsupplemented steers, but was otherwise unaffected as determined by other contrast comparisons (P ≥ 0.11).
There was a quadratic effect of Zn within RACsupplemented steers on serum IL-8 concentration (P = 0.02; Table 8 ), as serum IL-8 concentration decreased from Zn30R to Zn60R, but greatly increased from Zn60R to Zn90R. The RAC-supplemented steers had greater serum IL-8 concentration than non-RAC steers (P = 0.04), driven mostly by the greater IL-8 in Zn90R vs. Zn90. There was a tendency for CON steers to have lesser plasma cAMP concentrations than ZnAA-supplemented steers not supplemented with RAC (P = 0.09).
There was a tendency for a linear decrease in plasma haptoglobin as dietary Zn concentration increased within RAC-supplemented steers (P = 0.07; Table 8 ). During the RAC period, the CON steers had greater leukocyte numbers (P = 0.04) than other non-RAC, ZnAA-fed steers; however, within non-RAC steers, leukocyte numbers linearly increased with increased dietary Zn supplementation, driven mainly by the greater number of leukocytes in Zn60 steers (P = 0.03). Steers supplemented with RAC had greater leukocyte, lym- 1 Treatments: CON = no supplemental ZnAA (n = 5); Zn30 = 30 mg Zn/kg DM from ZnAA (n = 5); Zn30R = 30 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn60 = 60 mg Zn/kg DM from ZnAA (n = 6); Zn60R = 60 mg Zn/kg from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn90 = 90 mg Zn/kg DM from ZnAA (n = 5); Zn90R = 90 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6).
2 Contrasts = A: CON vs. Zn30, Zn60, Zn90; B: linear effect of ZnAA within RAC supplemented treatments (Zn30R, Zn60R, Zn90R); C: quadratic effect of ZnAA within RAC supplemented treatments (Zn30R, Zn60R, Zn90R); D: linear effect of ZnAA within non-RAC supplemented treatments (CON, Zn30, Zn60, Zn90); E: quadratic effect of ZnAA within non-RAC supplemented treatments (CON, Zn30, Zn60, Zn90); F: effect of RAC supplementation (Zn30, Zn60, and Zn90 vs. Zn30R, Zn60R, and Zn90R).
3 A 4% pencil shrink was applied to all live BW measures, which were used in the calculation of ADG and G:F. 4 Initial BW = Weights from d 86.
5 Day 86 values were used as covariates in analysis. Treatments: CON = no supplemental ZnAA (n = 5); Zn30 = 30 mg Zn/kg DM from ZnAA (n = 5); Zn30R = 30 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn60 = 60 mg Zn/kg DM from ZnAA (n = 6); Zn60R = 60 mg Zn/kg from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn90 = 90 mg Zn/kg DM from ZnAA (n = 5); Zn90R = 90 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6).
3 Day 0 body weights were used as a covariate in analysis.
phocyte, monocyte, eosinophil, and basophil numbers when compared with non-RAC, ZnAA steers (P < 0.05).
There was a tendency for Zn to linearly decrease eosinophil number within non-RAC steers (P = 0.06). Serum IL-6 concentration was again found to be below detection limits for all treatments. No differences between treatments were observed in tail length, percent DNA in tail, or tail moment (P ≥ 0.17) as measured by the comet assay to assess DNA damage in blood.
DISCuSSION
The β-agonist RAC acts through the G-protein coupled pathway to increase lipolysis and protein synthesis (Mersmann, 1998) , and in vitro and rodent data suggest that Zn may play a role in the G-proteincoupled receptor pathway, inhibiting cyclic nucleotide phosphodiesterase (PDE), an enzyme that degrades cAMP (Hojyo et al., 2011; von Bülow et al., 2005; Haase and Rink, 2007) . Dietary Zn supplementation could inhibit PDE and further increase cAMP concentrations in combination with β-agonists, thereby enhancing the signaling cascade and potentially resulting in greater lean muscle production. When RAC was supplemented in the present study increasing amounts of dietary ZnAA improved gains and feed efficiency linearly during the RAC feeding period. Similarly, pigs fed RAC for 2 weeks before finishing with ZnAA grew faster than pigs supplemented with an equivalent concentration of Zn from ZnSO 4 , or RAC alone (Patience and Chipman, 2011) .
The Zn90R steers had the greatest ADG and G:F in the RAC period, suggesting that when RAC is supplemented, Zn90 may be the optimum inclusion rate. However, because increasing inclusion of ZnAA in RAC diets linearly improved growth in this study it is unknown if a plateau in performance was reached. The NRC (2000) states that 30 mg Zn/kg diet DM is adequate to prevent deficiency of Zn in cattle. It is unclear whether the improvement in ADG and G:F in steers supplemented with both RAC and ZnAA up to 90 mg Zn/kg DM consuming a diet containing 88 mg Zn/kg (172 mg/kg total Zn) is due to a potential synergy with RAC, or alteration of Zn requirements in modern finishing cattle raised with growth-enhancing technology. More research is needed to separate these potential mechanisms. As the greatest concentration fed in this study was 90 mg Zn/kg DM from ZnAA, it is unknown whether there would be an additional benefit in supplementing RAC-fed cattle with greater Zn concentrations; however, further investigation seems warranted.
Despite the improvement in ADG in the RAC period when cattle received RAC and ZnAA supplementation, HCW was not influenced by RAC or Zn supplementation. It appears that performance during the pre-RAC period had a greater influence on the overall outcome of the study, possibly due to increased variation among the small number of steers utilized in the current study. However, in a larger follow-up study (9 pens per treatment, housing 6 steers each) lasting 84 to 91 d, carcass-adjusted final BW, overall ADG and G:F, and HCW were all increased in steers supplemented with 60 mg Zn/kg DM from ZnAA (150 mg Zn/kg DM total diet) in combination with RAC for 28 d, relative to steers receiving RAC alone (85 mg Zn/kg DM total diet; Genther-Schroeder et al., 2015) .
Source of Zn may be an important factor in enhancing RAC-responses, as Paulk et al. (2012) reported no benefit to pig performance when using Zn oxide in combination with RAC. Similarly, performance of 1 Treatments: CON = no supplemental ZnAA(n = 5); Zn30 = 30 mg Zn/kg DM from ZnAA (n = 5); Zn30R = 30 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn60 = 60 mg Zn/kg DM from ZnAA (n = 6); Zn60R = 60 mg Zn/kg from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn90 = 90 mg Zn/kg DM from ZnAA (n = 5); Zn90R = 90 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6).
2 Contrasts = A: CON vs. Zn30, Zn60, Zn90; B: linear effect of ZnAA within RAC supplemented treatments (Zn30R, Zn60R, Zn90R); C: quadratic effect of ZnAA within RAC supplemented treatments (Zn30R, Zn60R, Zn90R); D: linear effect of ZnAA within non-RAC supplemented treatments (CON, Zn30, Zn60, Zn90); E: quadratic effect of ZnAA within non-RAC supplemented treatments (CON, Zn30, Zn60, Zn90); F: effect of RAC supplementation (Zn30, Zn60, and Zn90 vs. Zn30R, Zn60R, and Zn90R (Bohrer et al., 2014; Edenburn et al., 2015) . Further work is needed to clarify the potential role of differing sources of Zn on the interaction with RAC-induced growth, as only ZnAA was utilized in the present study. During the pre-RAC period, supplementing 60 mg of Zn/kg diet DM as ZnAA tended to provide an improvement in performance. The supplementation of either 30 or 90 mg Zn/kg diet DM from ZnAA did not improve performance of steers compared with control steers during the pre-RAC period. Further work is needed to assess if 60 mg ZnAA/kg may be the optimum concentration to add to the diet when RAC is not supplemented, as previous research has shown little benefit to performance when supplementing well above the documented Zn requirement for finishing cattle (Malcolm-Callis et al., 2000) .
Although the supplemental Zn concentration in each diet in the present study was not less than 60 mg/kg diet DM, resulting in nearly 3 times the NRC (2000) recommendation for Zn in the CON diet (88 mg Zn/kg total diet), they do not appear to be pharmacological doses. Ott et al. (1966) reported plasma and liver Zn concentrations were relatively similar to those in the present study when supplementing 100 mg of Zn/kg diet DM to beef cattle for 12 wk but supplementing plethoric concentrations of inorganic Zn (500 or 2,100 mg/kg diet DM) increased plasma and liver Zn concentrations by 2 to 10 times cattle fed 100 mg/kg (344 and 1,304 mg/kg liver DM, respectively, assuming 25% liver DM; Ott et al., 1966) . The responses to Zn supplementation in the present study appear to be physiological and not pharmacological, based on the minimal changes in plasma and liver Zn concentrations relative to CON steers. This suggests that the supplemented Zn concentrations were not overwhelming homeostatic control mechanisms and accumulating in tissues (Spears and Hansen, 2008) .
In vitro experiments with bovine satellite cells have demonstrated increased cAMP production when Zn and RAC are used in combination, compared to RAC or Zn alone (Harris, 2013) , and Zn deficiency can increase PDE expression (Hojyo et al., 2011) . However, Zn supplementation alone has not been pre- 1 Treatments: CON = no supplemental ZnAA (n = 5); Zn30 = 30 mg Zn/kg DM from ZnAA (n = 5); Zn30R = 30 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn60 = 60 mg Zn/kg DM from ZnAA (n = 6); Zn60R = 60 mg Zn/kg from ZnAA and 300 mg×steer-1d-1 RAC (n = 6); Zn90 = 90 mg Zn/kg DM from ZnAA (n = 5); Zn90R = 90 mg Zn/kg DM from ZnAA and 300 mg×steer-1d-1 RAC (n = 6).
3 Day 78 values were used as covariates in analysis.
viously shown to increase cAMP concentrations in bovine satellite cells. In this study, plasma cAMP concentration tended to increase as dietary Zn increased during both the pre-RAC and RAC periods (in non-RAC fed steers). Any differences due to RAC may have been missed at sampling after 26 d of supplementation, as data indicate that almost 50% of βAR in porcine adipose tissue become down-regulated within 7 d of the initiation of RAC feeding (Spurlock et al., 1994) , indicating that cAMP concentrations may be greatest shortly after the initiation of RAC.
While others have noted a non-specific immune response when cattle are fed high-grain finishing diets (Ametaj et al., 2009; Berry et al., 2004) , this was not observed in the present study. However, during the RAC period, RAC increased leukocyte numbers, including lymphocytes, monocytes, basophils, and eosinophils and the proinflammatory chemokine IL-8 (Richman-Eisenstat et al., 1993; Feghali and Wright, 1997) . Increased numbers of these cell types and IL-8 are typical markers of inflammation (Germolec et al., 2010) . To the authors' knowledge, this is the first indication that supplementation of RAC may elicit an inflammatory response. These changes may reflect increased physiological stress elicited during RAC supplementation. Alternatively, the general increase in inflammatory markers could be a part of the mechanism of βAR desensitization, as cytokines can cause uncoupling of the receptor from adenylyl cyclase, decreasing cAMP production in rat cardiac myocytes (Chung et al., 1990) . In contrast, the majority of research suggests that β-agonists may suppress the immune response, as sheep treated with the β 2 -agonist clenbuterol were unable to produce an antibody response to immunization (Spencer and Oliver, 1996) and β-agonist administration causes inhibbition of pro-inflammatory cytokine production (Izeboud et al., 1999) . Linearly increasing Zn within RAC-supplemented steers linearly decreased haptoglobin, an anti-inflammatory acute-phase protein (Horadagoda et al., 1999) , but there was no overall effect of RAC on haptoglobin concentration. It is noteworthy that although the inflammatory measures were increased relative to controls, they were within the biologically normal range as reported by Kramer (2000) .
The transition metals Cu, Fe, and Zn are involved in nutritional immunity (Hood and Skaar, 2012) where Zn and Fe are sequestered from circulation, and the Cu-dependent acute phase protein ceruloplasmin is increased. Supplementation with RAC increased plasma Cu and decreased plasma Fe concentrations. Typically, plasma Zn concentrations decrease during an immune response; however, in the present study, supplementation with ZnAA may have prevented this decrease. In addition, both liver Cu and Zn concentrations were decreased linearly by ZnAA supplementation in combination with RAC. The changes found in this study suggest that trace mineral flux and requirements in response to RAC supplementation are not well understood, and further research is warranted.
In conclusion, under the conditions of this study supplementing ZnAA at 60 mg ZnAA/kg DM tended to improve performance during the initial 86 d of the 116-d finishing period. However, during the final 28 d, while RAC was included in the diet, supplementing 90 mg of ZnAA/kg DM had the greatest effect on the response to RAC, suggesting that the addition of Zn to diets of cattle fed RAC may improve performance. Changes in plasma Cu and Fe, leukocyte numbers, and serum IL-8 suggest that RAC may elicit a mild immune response, but further research is required to elucidate the cause of this response, as well as whether modulation of this response would influence growth performance in response to RAC.
